相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
Michael Basler et al.
GENES AND IMMUNITY (2020)
Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability
Ena Ladi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease
In Jun Yeo et al.
SCIENTIFIC REPORTS (2019)
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells
Roberta Ettari et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis
Elnaz Menhaji-Klotz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma
Roberta Ettari et al.
PHARMACOLOGY & THERAPEUTICS (2018)
The safety of bortezomib for the treatment of multiple myeloma
Guldane Cengiz Seval et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
Michael Basler et al.
EMBO REPORTS (2018)
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenannide)
Henry W. B. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
An inhibitor of proteasome beta 2 sites sensitizes myeloma cells to immunoproteasome inhibitors
Sondra Downey-Kopyscinski et al.
BLOOD ADVANCES (2018)
Safety of proteasome inhibitors for treatment of multiple myeloma
Danielle Schlafer et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes
Ruda de Luna Almeida Santos et al.
NATURE COMMUNICATIONS (2017)
Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice
Julia Koerner et al.
ONCOTARGET (2017)
Immunoproteasome 5i-Selective Dipeptidomimetic Inhibitors
Pradeep K. Singh et al.
CHEMMEDCHEM (2016)
A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit 5i
Eva M. Huber et al.
EMBO JOURNAL (2016)
Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice
Esilida Sula Karreci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine
Christian Dubiella et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques
Jessica Welter et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2015)
The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Zachary Miller et al.
CURRENT CANCER DRUG TARGETS (2014)
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Lenka Kubiczkova et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
Denise Niewerth et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Peptide-Based Proteasome Inhibitors in Anticancer Drug Design
Nicola Micale et al.
MEDICINAL RESEARCH REVIEWS (2014)
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors
Denise Niewerth et al.
HAEMATOLOGICA (2013)
Purification and separation of the 20S immunoproteasome from the constitutive proteasome and identification of the subunits by LC-MS
Vincent Dechavanne et al.
PROTEIN EXPRESSION AND PURIFICATION (2013)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
Immune and non-immune functions of the immunoproteasome
Arkhjamil Angeles et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2012)
The Immunoproteasome as a Target in Hematologic Malignancies
Deborah J. Kuhn et al.
SEMINARS IN HEMATOLOGY (2012)
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
Christopher Blackburn et al.
BIOCHEMICAL JOURNAL (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Design, Synthesis, Biological Evaluation, and Structure-Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the SAR of α-Amino Acid Boronates
Yongqiang Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Novel prodrugs of tegafur that display improved anticancer activity and Antiangiogenic properties
Dikla Engel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells
M Altun et al.
CANCER RESEARCH (2005)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Approval summary for bortezomib for injection in the treatment of multiple myeloma
PF Bross et al.
CLINICAL CANCER RESEARCH (2004)
The structure of the mammalian 20S proteasome at 2.75 Å resolution
M Unno et al.
STRUCTURE (2002)
Tumor necrosis factor-α induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface
K Hallermalm et al.
BLOOD (2001)
Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats
C Noda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Isolation and characterization of bovine thymus multicatalytic proteinase complex
AM Eleuteri et al.
PROTEIN EXPRESSION AND PURIFICATION (2000)
分享论文
